# OnCo record afatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/afatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "afatinib" ;
  schema:name "Afatinib"@en ;
  schema:description "Afatinib (Gilotrif) is a second-generation pill that binds EGFR, HER2 and HER4 irreversibly, approved in 2013 for EGFR-mutant lung cancer. Its lasting value is activity against the uncommon EGFR mutations G719X, L861Q and S768I, approved in 2018, because osimertinib has displaced it for common mutations and its wild-type EGFR binding causes more rash and diarrhoea."@en ;
  schema:url <https://onco.cc/drugs/afatinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Afatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q4688818> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=afatinib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule pan-ErbB TKI (second generation, irreversible)" ;
  schema:alternateName "Gilotrif / Giotrif" ;
  onco:approval "US 2013: First-line metastatic NSCLC with EGFR exon 19 del or L858R", "US 2016: Squamous NSCLC after platinum", "US 2018: Uncommon EGFR mutations (S768I, L861Q, G719X)", "EU 2013: EU brand Giotrif" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> ;
  onco:trials <https://onco.cc/trials/nct03785249/>, <https://onco.cc/trials/lux-lung-3/> .